Выгоды и риски интеграции Российских фармацевтических компаний в глобальные цепочки стоимости / Benefits and risks of integrating Russian pharmaceutical companies into global value chains

Конева Валерия Вячеславовна

Аннотация


The development of globalization and internationalization has led to the emergence of global value chains, which has significantly changed national and world economies. Global value chains (GVCs) are a list of activities carried out by companies from the creation of an idea to the presentation of the final product. The main feature of global value chains is the redistribution of these activities around the world with different benefits for their participants. But in addition to the benefits, countries and companies have associated risks in their integration. Potential benefits include increased efficiency of companies and countries as well as increased competitiveness. The risks are an increase in supply and demand for cheap labor, mainly in developing countries. By redistributing production processes to developing countries with cheap labor, developed countries receive the benefits of concentration at the R&D stage. That is why it is necessary to conduct a study of global value chains in the global production system, identifying modern concepts and the risks and benefits of integrating into them. It should also be noted the special integration of global value chains into the pharmaceutical industry and their wide applicability by pharmaceutical companies.
The relevance of the study is due to the increasing importance of global value chains in the world economy and their impact on the pharmaceutical industry. The object of the study are pharmindustrial global value chains. The subject of the study are risks and benefits of integrating into global value chains by the pharmaceutical company in Russia on the example of pharmaceutical
companies in developed countries.
The aim of the study is the formation of a theoretical platform for identifying global value chains in the pharmaceutical industry.
The research revealed the main conclusions:
- the terminology, modern concepts, risks and benefits, the essence of the study are clarified;
- generalized and structured features, trends in the development of the global pharmaceutical market, including on the basis of the results of a comparative analysis of pharmaceutical companies and countries, including Russia;
- highlighted the benefits and risks of integrating pharmaceutical companies into global value chains, provided recommendations for Russian pharmaceutical companies for further successful integration into them.